Wedbush Equities Analysts Lower Earnings Estimates for YMAB

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) – Equities researchers at Wedbush dropped their Q1 2025 EPS estimates for shares of Y-mAbs Therapeutics in a note issued to investors on Tuesday, March 4th. Wedbush analyst D. Nierengarten now forecasts that the company will earn ($0.23) per share for the quarter, down from their prior forecast of ($0.13). Wedbush currently has a “Outperform” rating and a $23.00 target price on the stock. The consensus estimate for Y-mAbs Therapeutics’ current full-year earnings is ($0.65) per share. Wedbush also issued estimates for Y-mAbs Therapeutics’ Q2 2025 earnings at ($0.25) EPS, Q3 2025 earnings at ($0.26) EPS, Q4 2025 earnings at ($0.25) EPS, FY2025 earnings at ($1.00) EPS, FY2026 earnings at ($1.09) EPS, FY2027 earnings at ($1.27) EPS and FY2028 earnings at ($1.39) EPS.

YMAB has been the subject of several other reports. Brookline Capital Management initiated coverage on Y-mAbs Therapeutics in a report on Thursday, December 5th. They issued a “buy” rating and a $17.00 price objective for the company. Oppenheimer started coverage on Y-mAbs Therapeutics in a research note on Monday, November 18th. They set an “outperform” rating and a $23.00 target price for the company. Truist Financial dropped their target price on Y-mAbs Therapeutics from $21.00 to $18.00 and set a “buy” rating for the company in a report on Wednesday. HC Wainwright reiterated a “buy” rating and set a $22.00 price target on shares of Y-mAbs Therapeutics in a report on Monday, January 13th. Finally, Morgan Stanley reduced their price target on Y-mAbs Therapeutics from $11.00 to $7.00 and set an “underweight” rating on the stock in a research report on Wednesday. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $19.30.

Y-mAbs Therapeutics Stock Up 8.2 %

Shares of YMAB opened at $5.25 on Friday. The company has a market cap of $235.14 million, a PE ratio of -9.72 and a beta of 0.65. The business has a fifty day moving average of $6.39 and a 200 day moving average of $10.58. Y-mAbs Therapeutics has a 52-week low of $4.25 and a 52-week high of $18.17.

Y-mAbs Therapeutics (NASDAQ:YMAB) last issued its quarterly earnings data on Tuesday, March 4th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.02). Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. The business had revenue of $26.50 million during the quarter, compared to the consensus estimate of $26.70 million. During the same quarter last year, the company earned ($0.02) EPS.

Institutional Investors Weigh In On Y-mAbs Therapeutics

Large investors have recently modified their holdings of the stock. Principal Financial Group Inc. boosted its position in shares of Y-mAbs Therapeutics by 9.4% in the fourth quarter. Principal Financial Group Inc. now owns 22,197 shares of the company’s stock worth $174,000 after buying an additional 1,903 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Y-mAbs Therapeutics by 12.6% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,818 shares of the company’s stock worth $179,000 after buying an additional 2,545 shares during the period. JPMorgan Chase & Co. boosted its position in shares of Y-mAbs Therapeutics by 10.4% in the third quarter. JPMorgan Chase & Co. now owns 30,335 shares of the company’s stock worth $399,000 after buying an additional 2,854 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of Y-mAbs Therapeutics in the third quarter worth $44,000. Finally, SG Americas Securities LLC boosted its position in shares of Y-mAbs Therapeutics by 30.7% in the fourth quarter. SG Americas Securities LLC now owns 17,729 shares of the company’s stock worth $139,000 after buying an additional 4,163 shares during the period. 70.85% of the stock is owned by institutional investors.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.